Lethargic Encephalitis

Neal, Josephine B.

doi:10.1001/archneurpsyc.1919.02180090021003

Cited by 14 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dunn and Beagley (22) reported pressure of seven to fifteen millimeters of mercury, clear with an average cell count of nine. Neal (51) in forty cases found slight to moderate increase of cell count i'n thirty-three cases, absent in seven. Increased protein in all but one case, gold curves in three cases but not characteristic, spinal fluid usually under moderate pressure, and clear.…”

Section: -Li-mentioning

confidence: 92%

See 1 more Smart Citation

Chronic Epidemic Encephalitis.

Wimmer¹

1925

JAMA

View full text Add to dashboard Cite

Section: -Li-mentioning

confidence: 92%

“…,--15-Neal (51) in a review of forty cases states that she found a slight leucocytosis, but other blood findings apparently normal, as the usual findings were.…”

Section: -Li-mentioning

confidence: 96%

Chronic Epidemic Encephalitis.

Wimmer¹

1925

JAMA

View full text Add to dashboard Cite

“…Its connotations included peripheral muscular fatigue and also ''neuroses'' such as neurasthenia. 35,36 Asthenia was reported in half of an acute EL series 37 and in 28% of a postencephalitic series. 23 Stern equated asthenia with muscle hypotonia (Ref.…”

Section: Asthenia and Fatiguementioning

confidence: 98%

On doing nothing: Descriptions of sleep, fatigue, and motivation in encephalitis lethargica

Ward

2011

Movement Disorders

View full text Add to dashboard Cite

Epidemics of encephalitis lethargica (EL), from 1917 to the 1930s, are an important milestone in the history of movement disorders. Today, the two best-known features of EL are somnolence and parkinsonism but the full clinical picture was variable and complex. States of wakeful inactivity--as opposed to drowsiness--were often described both in the acute and postacute stages and were referred to in the EL literature as "lethargy" or "torpor." The study described here is based on a survey of clinical descriptions published in English, French, and German from 1917 to 1942. Its focus is on the history of clinical ideas, rather than applying modern pathophysiological concepts retrospectively. Descriptions of lethargy are explored as a way of elucidating concepts of sleep, fatigue, and motivation during the study period. The literature described many patients who had (1) lethargy without interruption in consciousness; (2) slowness of movement and catalepsy without other prominent parkinsonian features; and (3) apathy and lack of initiative without severe disorders of mood or thought content. Hence observers distinguished a state of wakeful inactivity from primary disorders of sleep, movement and behavior. Contemporaneous accounts suggest that writers had difficulty in reconciling their observations with preexisting concepts; there still may be limitations in our ability to describe and classify the clinical states connected during the epidemic era with the term "lethargy."

show abstract

“…Its connotations included peripheral muscular fatigue and also “neuroses” such as neurasthenia 35, 36. Asthenia was reported in half of an acute EL series37 and in 28% of a postencephalitic series 23. Stern equated asthenia with muscle hypotonia (Ref 30,.…”

Section: Lethargy As a Sleep Disordermentioning

confidence: 99%

Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck

Gilbert

Cmelak

Shyr

et al. 2008

Cancer

View full text Add to dashboard Cite

BACKGROUND.Patients with recurrent or metastatic HNC have a poor response and survival with currently available chemotherapy agents. Thus, new agents are needed. The authors report the results of a phase II trial of irinotecan and cisplatin in patients with metastatic or recurrent HNC.METHODS.Patients were treated with irinotecan 65 mg/m2 IV over 90 minutes and cisplatin 30 mg/m2 were administered intravenously weekly for four weeks, followed by a two week rest. However, after 17 patients were treated with weekly irinotecan at a dose of 65 mg/m2, toxicity analysis demonstrated the poor tolerance of that dose in this patient population. Thus, the protocol was amended, and irinotecan was dose reduced to a starting dose of 50 mg/m2. Twenty‐three additional patients were treated with this dose.RESULTS.Forty patients were enrolled on study between February 2002 and April 2006, 17 patients at the first dose level and 23 patients at the amended dose level. Overall, 12 of 17 patients (71%) treated with irinotecan 65 mg/m2 experienced clinically significant grade 3 or 4 toxicity. Twelve patients required dose reductions. Toxicity was reduced but 17% of patients still experienced grade 3 or 4 toxicity on the lower irinotecan dose. The response rate was 35% for patients treated at irinotecan 65 mg/m2 and 22% for patients treated at 50 mg/m2. No complete responses were noted.CONCLUSIONS.The combination of irinotecan and cisplatin is efficacious in a poor prognosis group of patients but toxicity is substantial. Cancer 2008. © 2008 American Cancer Society.

show abstract

Lethargic Encephalitis

Cited by 14 publications

References 0 publications

Chronic Epidemic Encephalitis.

Chronic Epidemic Encephalitis.

On doing nothing: Descriptions of sleep, fatigue, and motivation in encephalitis lethargica

Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck

Contact Info

Product

Resources

About